Why Is Amneal Pharmaceuticals Stock Gaining Today?

Benzinga_recent_news04-22

Amneal Pharmaceuticals (NASDAQ:AMRX) shares are up during Wednesday’s premarket session as the company has entered into a definitive agreement to acquire Kashiv BioSciences. Amenal stock is up 3.76%, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629048030?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/22/Pharmacy--Pills-And-Box-With-Healthcare-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-22 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629048030","market":"us","top_or_hot":-1,"title":"Why Is Amneal Pharmaceuticals Stock Gaining Today?","media":"Benzinga_recent_news","content":"<div>\n<p>Amneal Pharmaceuticals (NASDAQ:AMRX) shares are up during Wednesday’s premarket session as the company has entered into a definitive agreement to acquire Kashiv BioSciences.\nAmenal stock is up 3.76%, ...</p>\n\n<a href=\"https://www.benzinga.com/m-a/26/04/51963380/why-is-amneal-pharmaceuticals-stock-gaining-today\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Amneal Pharmaceuticals Stock Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Amneal Pharmaceuticals Stock Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/m-a/26/04/51963380/why-is-amneal-pharmaceuticals-stock-gaining-today><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amneal Pharmaceuticals (NASDAQ:AMRX) shares are up during Wednesday’s premarket session as the company has entered into a definitive agreement to acquire Kashiv BioSciences.\nAmenal stock is up 3.76%, ...</p>\n\n<a href=\"https://www.benzinga.com/m-a/26/04/51963380/why-is-amneal-pharmaceuticals-stock-gaining-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4217","symbol_name":"自存仓储房地产信托","start_time":0,"source_url":"https://www.benzinga.com/m-a/26/04/51963380/why-is-amneal-pharmaceuticals-stock-gaining-today","article_id":"2629048030","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/22/Pharmacy--Pills-And-Box-With-Healthcare-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/m-a/26/04/51963380/why-is-amneal-pharmaceuticals-stock-gaining-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629048030","pubTimestamp":1776856500,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4217":"自存仓储房地产信托","BK4007":"制药","AMRX":"Amneal Pharmaceuticals, Inc.","SMA":"Smartstop Self Storage REIT Inc","BK4150":"赌场与赌博","RSI":"Rush Street Interactive, Inc."},"translate_title":"为什么Amneal Pharmaceuticals股票今天上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSI":1,"SMA":1,"AMRX":1},"content_text":"Amneal Pharmaceuticals (NASDAQ:AMRX) shares are up during Wednesday’s premarket session as the company has entered into a definitive agreement to acquire Kashiv BioSciences.\nAmenal stock is up 3.76%, as the acquisition aims to create a global leader in biosimilars.\nThis strategic move is expected to position Amneal to capitalize on a projected $300 billion global biologics loss-of-exclusivity opportunity, enhancing its growth profile while raising its full-year guidance for 2026, as detailed in the recent announcement.\nThe acquisition involves a total consideration of $1.1 billion, which includes $375 million in cash and $375 million in equity payable at closing, along with potential milestone payments.\nThe transaction is subject to shareholder and regulatory approvals, with expectations for completion in the second half of 2026.\nAs of Dec. 31, 2025, the firm had cash and equivalents worth $282.029 million.\n“This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale,” said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal.\n“By combining Kashiv’s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward.”\nAmneal Pharmaceuticals is currently trading within a strong upward trend, sitting 17.6% above its 200-day simple moving average (SMA), which suggests a bullish long-term outlook. The stock is also 6.1% above its 20-day SMA, indicating positive short-term momentum, while remaining 1.5% above its 50-day SMA, reflecting a stable intermediate trend.\nThe relative strength index (RSI) is at 51.90, suggesting the stock is in neutral territory, indicating a balanced market sentiment without strong buying or selling pressure. This positioning allows for potential upward movement if buying interest increases.\nThe acquisition of Kashiv BioSciences is significant as it enhances Amneal’s capabilities in the biosimilars market, which is expected to grow substantially in the coming years.\nThis strategic move not only diversifies its product offerings but also positions the company to take advantage of the impending loss of exclusivity for several biologic drugs.\nAmneal Pharmaceuticals is set to report earnings on May 1, 2026 (confirmed).\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $17.00. Recent analyst moves include:\nSignificance: Because AMRX carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.\nAMRX Stock Price Activity: Amneal Pharmaceuticals shares were up 3.76% at $13.51 during premarket trading on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629048030","isCrawlerRequest":true}